MedTrace Logo

Pharmacodynamics of Mitiglinide/Sitagliptin Compared to Mitiglinide and Sitagliptin

NCT01422590 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2011-09-07

No results posted yet for this study

Summary

1. Explore pharmacodynamics

* glucose
* insulin
* C-peptide
* glucagon
* intact GLP-1
* DPP-4 activity
* CGMS (continuous glucose monitoring system)
2. Assess Safety

* adverse events
* clinical laboratory test
* physical examination

Conditions

Interventions

DRUG

Sitagliptin

Single oral administration of sitagliptin 100 mg

DRUG

Mitiglinide

Single oral administration of mitiglinide 10 mg

DRUG

Sitagliptin, Mitiglinide

Concomitant administration of sitagliptin 100 mg and mitiglinide 10 mg

Sponsors & Collaborators

Principal Investigators

  • Wooseong Hur, MD, PhD · Samsung Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2011-04-30
Completion
2011-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01422590 on ClinicalTrials.gov